TScan Therapeutics, Inc. (TCRX) Financials

TCRX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 272.1 million 121.3 million
2023-09-30 291.4 million 122.4 million
2023-06-30 316.9 million 126.3 million
2023-03-31 173.6 million 95.6 million

TCRX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -24.2 million 1.5 million
2023-09-30 6.6 million 1.3 million
2023-06-30 -22.4 million 1.2 million
2023-03-31 -24.4 million 1.1 million

TCRX Net Income

No data available :(

TCRX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 192.0 million - 62.4 million
2023-09-30 155.2 million - 57.0 million
2023-06-30 208.8 million - 58.0 million
2023-03-31 95.6 million - 55.8 million

TCRX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 94.8 million
2023-09-30 94.8 million
2023-06-30 47.2 million
2023-03-31 24.2 million

TCRX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 469000 22.4 million 6.2 million 1.3 million
2023-09-30 1.4 million 22.7 million 5.9 million -
2023-06-30 420000 21.2 million 6.5 million -
2023-03-31 838000 21.8 million 7.8 million -

TCRX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 7.2 million 1.3 million
2023-09-30 3.9 million 1.3 million
2023-06-30 3.1 million 1.3 million
2023-03-31 6.8 million 1.5 million

TCRX

Price: $8.56

52 week price:
1.62
9.00

Earnings Per Share: -1.36 USD

P/E Ratio: -2.59

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 133500

Market Capitalization: 371.3 million

Average Dividend Frequency: 4

Links: